FOR IMMEDIATE RELEASE DATE: October 9, 2023 Contact: Lisa Owens, 210-601-6647 NEXT Oncology and MediLink Therapeutics Take “Team Approach” to Next Level on Phase 1 First in Human Clinical Trial in San Antonio (SAN ANTONIO, TX and CAMBRIDGE, MA) October 9, 2023 –– MediLink Therapeutics and NEXT Oncology are collaborating on a Phase 1 First in Human Clinical trial for …
Video: Expanded Phase 1 Program to the Dallas Area
In this video hosted by Oncology Tube, Anthony Tolcher, MD, discusses Cancer Drug Research: Expanded Phase 1 Program to the Dallas Area. iFrame is not supported!
SA cancer research company entering Dallas market as it eyes more U.S., European expansion
A cancer research company based in San Antonio is entering the Dallas market as it eyes more U.S. and European expansion… Read the full article at the San Antonio Business Journal.
NEXT Oncology Expands Phase I Program to Dallas Area
Expansion makes new break-through anticancer therapies closer to home for more Texans (DALLAS) April 12, 2023 –– Internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, continues to increase access to world-class Phase I cancer research and the latest in new agents and anticancer treatments with the opening of NEXT Oncology – Dallas. NEXT Dallas is …
Grand Opening of joint venture brings access to proprietary Phase I program to more patients
NEXT-Virginia Opens Phase I Clinical Research Clinic for Oncology Patients in collaboration with Virginia Cancer Specialists. (SAN ANTONIO) January 9, 2023 –– Dr. Alexander I. Spira of Virginia Cancer Specialists (VCS) and Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, are pleased to announce the grand opening of their joint venture, NEXT Virginia, on January 12 to expand access to …
Teon Therapeutics Announces First Patient Treated in Phase 1/2 Clinical Trial of TT-816, a Novel Oral Immune Checkpoint Inhibitor, in Patients with Advanced Solid Tumors
Multi-center Phase 1/2 study to evaluate safety and efficacy of TT-816, an oral CB2 receptor antagonist acting as an immune checkpoint inhibitor while promoting T cell infiltration of cold tumors and stimulating NK cell tumor killing – Cannabinoid CB2 receptors are found in many difficult-to-treat cancers, including lung, renal, and ovarian cancers – Inhibiting CB2 receptors has the potential to …
The Theresa Mays Endowed Merit Award Established for Promising Investigators Holding a PharmD Degree
(SAN ANTONIO) November 1, 2022 –– The Theresa Mays Endowed Merit Award has been established to promote the education and advancement of oncology research for pharmacists. The award has been established with the support of friends and colleagues to recognize the life and legacy of Theresa Mays, BS, PharmD, BCOP, FASHP, and Vice President of Investigational Drug Services at NEXT …
NEXT Oncology Selects proXimityTM to Automate Data Transfer for Clinical Trials
System will accelerate performance evaluation of new drugs in early phase research for cancer patients. (SAN ANTONIO) October 17, 2022 –– NEXT Oncology has selected proXimityTM as the exclusive tool to automate the transfer of clinical trial data from their electronic medical record (EMR) to the electronic data capture (EDC) systems used by sponsor organizations doing clinical trials with NEXT …
NEXT Oncology’s Dr. Anthony Tolcher Presents Data on Well-Tolerated Monotherapy
for Advanced and Metastatic Tumors at ESMO Congress 2022
DCC-3116 is a first-in-class inhibitor of autophagy. (SAN ANTONIO) September 16, 2022 –– Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, returned from the European Society for Medical Oncology (ESMO) in Paris, France, where he presented the findings of a phase I, first-in-human study that evaluates DCC-3116 alone and in combination with MAPK pathway inhibition in patients with MAPK …
Virginia Cancer Patient “Living with (Stage 4) Cancer” Thanks to Clinical Trial
Dr. Alexander I. Spira presented promising research findings at The American Societyof Clinical Oncology (ASCO) to help those with lung cancer. (FAIRFAX, VIRGINIA) June 27, 2022 –– Chuck Tonkin, 82, has been battling cancer since 2018. Now with stage 4 lung cancer, with metastatic disease to his brain, has found a new drug, adagrasib, that is giving him his life …
- Page 1 of 2
- 1
- 2